Literature DB >> 24269767

Localization of non-linear neutralizing B cell epitopes on ricin toxin's enzymatic subunit (RTA).

Joanne M O'Hara1, Jane C Kasten-Jolly2, Claire E Reynolds2, Nicholas J Mantis3.   

Abstract

Efforts to develop a vaccine for ricin toxin are focused on identifying highly immunogenic, safe, and thermostable recombinant derivatives of ricin's enzymatic A subunit (RTA). As a means to guide vaccine design, we have embarked on an effort to generate a comprehensive neutralizing and non-neutralizing B cell epitope map of RTA. In a series of previous studies, we identified three spatially distinct linear (continuous), neutralizing epitopes on RTA, as defined by monoclonal antibodies (mAbs) PB10 (and R70), SyH7, and GD12. In this report we now describe a new collection of 19 toxin-neutralizing mAbs that bind non-linear epitopes on RTA. The most potent toxin-neutralizing mAbs in this new collection, namely WECB2, TB12, PA1, PH12 and IB2 each had nanamolar (or sub-nanomolar) affinities for ricin and were each capable of passively protecting mice against a 5-10xLD50 toxin challenge. Competitive binding assays by surface plasmon resonance revealed that WECB2 binds an epitope that overlaps with PB10 and R70; TB12, PA1, PH12 recognize epitope(s) close to or overlapping with SyH7's epitope; and GD12 and IB2 recognize epitopes that are spatially distinct from all other toxin-neutralizing mAbs. We estimate that we have now accounted for ∼75% of the predicted epitopes on the surface of RTA and that toxin-neutralizing mAbs are directed against a very limited number of these epitopes. Having this information provides a framework for further refinement of RTA mutagenesis and vaccine design.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody; Epitope; Toxin; Vaccine

Mesh:

Substances:

Year:  2013        PMID: 24269767      PMCID: PMC4070743          DOI: 10.1016/j.imlet.2013.11.009

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  33 in total

Review 1.  Retrograde transport of protein toxins through the Golgi apparatus.

Authors:  Kirsten Sandvig; Tore Skotland; Bo van Deurs; Tove Irene Klokk
Journal:  Histochem Cell Biol       Date:  2013-06-14       Impact factor: 4.304

2.  Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine.

Authors:  Ellen S Vitetta; Joan E Smallshaw; John Schindler
Journal:  Clin Vaccine Immunol       Date:  2012-08-22

3.  Effect of single-point mutations on the stability and immunogenicity of a recombinant ricin A chain subunit vaccine antigen.

Authors:  Justin C Thomas; Joanne M O'Hara; Lei Hu; Fei P Gao; Sangeeta B Joshi; David B Volkin; Robert N Brey; Jianwen Fang; John Karanicolas; Nicholas J Mantis; C Russell Middaugh
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

4.  Protective effect of two recombinant ricin subunit vaccines in the New Zealand white rabbit subjected to a lethal aerosolized ricin challenge: survival, immunological response, and histopathological findings.

Authors:  Daniel E McLain; Bridget S Lewis; Jennifer L Chapman; Robert W Wannemacher; Changhong Y Lindsey; Leonard A Smith
Journal:  Toxicol Sci       Date:  2011-10-10       Impact factor: 4.849

5.  Arginine residues on the opposite side of the active site stimulate the catalysis of ribosome depurination by ricin A chain by interacting with the P-protein stalk.

Authors:  Xiao-Ping Li; Peter C Kahn; Jennifer Nielsen Kahn; Przemyslaw Grela; Nilgun E Tumer
Journal:  J Biol Chem       Date:  2013-09-03       Impact factor: 5.157

6.  Resolution of two overlapping neutralizing B cell epitopes within a solvent exposed, immunodominant α-helix in ricin toxin's enzymatic subunit.

Authors:  David J Vance; Nicholas J Mantis
Journal:  Toxicon       Date:  2012-06-29       Impact factor: 3.033

7.  Neutralizing monoclonal antibodies against ricin's enzymatic subunit interfere with protein disulfide isomerase-mediated reduction of ricin holotoxin in vitro.

Authors:  Joanne M O'Hara; Nicholas J Mantis
Journal:  J Immunol Methods       Date:  2013-06-15       Impact factor: 2.303

8.  Identification of hypoglycemia in mice as a surrogate marker of ricin toxicosis.

Authors:  Seth H Pincus; Leta Eng; Corrie L Cooke; Massimo Maddaloni
Journal:  Comp Med       Date:  2002-12       Impact factor: 0.982

9.  A novel recombinant vaccine which protects mice against ricin intoxication.

Authors:  Joan E Smallshaw; Ana Firan; John R Fulmer; Stephen L Ruback; Victor Ghetie; Ellen S Vitetta
Journal:  Vaccine       Date:  2002-09-10       Impact factor: 3.641

10.  Sub-domains of ricin's B subunit as targets of toxin neutralizing and non-neutralizing monoclonal antibodies.

Authors:  Anastasiya Yermakova; David J Vance; Nicholas J Mantis
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

View more
  21 in total

1.  Recent advances in the development of vaccines against ricin.

Authors:  Robert N Brey; Nicholas J Mantis; Seth H Pincus; Ellen S Vitetta; Leonard A Smith; Chad J Roy
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

2.  Using homology modeling to interrogate binding affinity in neutralization of ricin toxin by a family of single domain antibodies.

Authors:  Andrea Bazzoli; David J Vance; Michael J Rudolph; Yinghui Rong; Siva Krishna Angalakurthi; Ronald T Toth; C Russell Middaugh; David B Volkin; David D Weis; John Karanicolas; Nicholas J Mantis
Journal:  Proteins       Date:  2017-08-04

3.  Structural Analysis of Single Domain Antibodies Bound to a Second Neutralizing Hot Spot on Ricin Toxin's Enzymatic Subunit.

Authors:  Michael J Rudolph; David J Vance; Michael S Cassidy; Yinghui Rong; Nicholas J Mantis
Journal:  J Biol Chem       Date:  2016-11-30       Impact factor: 5.157

4.  Chimeric plantibody passively protects mice against aerosolized ricin challenge.

Authors:  Erin K Sully; Kevin J Whaley; Natasha Bohorova; Ognian Bohorov; Charles Goodman; Do H Kim; Michael H Pauly; Jesus Velasco; Ernie Hiatt; Josh Morton; Kelsi Swope; Chad J Roy; Larry Zeitlin; Nicholas J Mantis
Journal:  Clin Vaccine Immunol       Date:  2014-02-26

5.  Crystal structures of ricin toxin's enzymatic subunit (RTA) in complex with neutralizing and non-neutralizing single-chain antibodies.

Authors:  Michael J Rudolph; David J Vance; Jonah Cheung; Matthew C Franklin; Fiana Burshteyn; Michael S Cassidy; Ebony N Gary; Cristina Herrera; Charles B Shoemaker; Nicholas J Mantis
Journal:  J Mol Biol       Date:  2014-06-04       Impact factor: 5.469

6.  High-Resolution Epitope Positioning of a Large Collection of Neutralizing and Nonneutralizing Single-Domain Antibodies on the Enzymatic and Binding Subunits of Ricin Toxin.

Authors:  David J Vance; Jacqueline M Tremblay; Yinghui Rong; Siva Krishna Angalakurthi; David B Volkin; C Russell Middaugh; David D Weis; Charles B Shoemaker; Nicholas J Mantis
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

Review 7.  Protein Structure Facilitates High-Resolution Immunological Mapping.

Authors:  Madison Zuverink; Joseph T Barbieri
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

8.  Novel Ricin Subunit Antigens With Enhanced Capacity to Elicit Toxin-Neutralizing Antibody Responses in Mice.

Authors:  Newton Wahome; Erin Sully; Christopher Singer; Justin C Thomas; Lei Hu; Sangeeta B Joshi; David B Volkin; Jianwen Fang; John Karanicolas; Donald J Jacobs; Nicholas J Mantis; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2016-03-15       Impact factor: 3.534

9.  Humanized Monoclonal Antibody That Passively Protects Mice against Systemic and Intranasal Ricin Toxin Challenge.

Authors:  Greta Van Slyke; Erin K Sully; Natasha Bohorova; Ognian Bohorov; Do Kim; Michael H Pauly; Kevin J Whaley; Larry Zeitlin; Nicholas J Mantis
Journal:  Clin Vaccine Immunol       Date:  2016-09-06

Review 10.  Progress and challenges associated with the development of ricin toxin subunit vaccines.

Authors:  David J Vance; Nicholas J Mantis
Journal:  Expert Rev Vaccines       Date:  2016-04-06       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.